Health
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase
About this update from Biovie Inc.
[{"type":"image","alt":"BioVie, Inc.","displaySize":"","headline":null,"caption":"BioVie, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/74wuLVBY92R9d2c1AJ.QhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a","width":300,"height":79}},"lazy":false},{"type":"text","content":"Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participation","length":115,"tagName":"p"},{"type":"text","content":"CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27-30, 2025.","length":558,"tagName":"p"},{"type":"text","content":"People with Parkinson’s disease (PD) often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and geographic constraints. SUNRISE-PD is a Phase 2 trial evaluating bezisterim (NE3107) in individuals with early-stage PD that aims to address these challenges through a hybrid, decentralized design. The trial allows participants to complete visits either at home or in a clinic, improving access and flexibility. The presentation at ATMRD highlights this patient-focused approach and its potential to broaden participation in PD research.","length":609,"tagName":"p"},{"type":"text","content":"“SUNRISE-PD represents the future of clinical trial design one that meets people where they are and makes participation possible without compromising scientific rigor,” said Cuong Do, President and CEO of BioVie Inc. “By combining an innovative therapeutic approach with a decentralized model, we are exploring the potential of bezisterim to impact the course of Parkinson’s disease and set a precedent for...